Michael J Payette, M.D., M.B.A.

Verified facts

What the public records show

CMS Open Payments records show Michael J Payette, M.D., M.B.A. received $851,481.87 in general payments during 2025 across 954 reported records.

UCB, Inc. accounted for 16.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 30 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Opzelura, Rinvoq, Sotyktu, Tremfya, Zoryve.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rinvoq by this doctor in 2024.

Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Zoryve by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sotyktu as an associated drug or biological on 35607 records involving 9242 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sotyktu by this doctor in 2024.

Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Opzelura by this doctor in 2024.

Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tremfya by this doctor in 2024.

Kowa Pharmaceuticals America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZORYVE as an associated drug or biological on 22731 records involving 10996 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Zoryve by this doctor in 2024.

Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JUBLIA as an associated drug or biological on 5397 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jublia by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.